Drug intelligence / Profile preview

linezolid + teicoplanin

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intravenous, Intramuscular

Overview

A combination of two antibacterial agents used against Gram-positive infections, particularly in critically ill patients. Linezolid is an oxazolidinone that inhibits bacterial protein synthesis by preventing the formation of the initiation complex, binding to the 23S portion of the 50S ribosomal subunit. Teicoplanin is a glycopeptide antibiotic that inhibits peptidoglycan polymerization, resulting in inhibition of bacterial cell wall synthesis and cell death.

Targets

D-Ala-D-Ala (D-Ala-D-Ala terminus)PTC (50S ribosomal peptidyl transferase center)

Beyond the preview

Go deeper on linezolid + teicoplanin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on linezolid + teicoplanin.

Explore the full profile